Striatal Plasticity and Relapse Risk in Anorexia Nervosa: Implications for Neuromodulatory Research

Striatal Reorganization Predicts Relapse Risk in Anorexia Nervosa

Longitudinal neuroimaging research published on October 26, 2026, demonstrates that changes in the striatal putamen gradient—specifically, posterior-anterior reorganization—are associated with relapse risk in individuals recovering from anorexia nervosa (AN). The study, available via OpenAlex, combined mouse models and human cohorts to identify striatal plasticity as a candidate biomarker for vulnerability to relapse after weight restoration.

In the study, women with AN (n = 71) exhibited reduced striatal volumes at baseline compared to healthy controls (n = 30). After weight restoration, a subset (n = 41) was reassessed, revealing substantial recovery of striatal volumes. However, the degree and pattern of posterior-anterior putamen gradient change differed between those who achieved remission and those who relapsed, with right putamen changes predicting future relapse. These findings were mirrored in a mouse model (VAChTcKO), which displayed reduced dorsolateral striatal volume and maladaptive eating behaviors.

Mechanisms: Striatal Circuits, Reward Processing, and Behavioral Control

Striatal plasticity, particularly in the putamen, underpins the balance between goal-directed and habitual behavior, both of which are disrupted in AN. The research found that individuals with greater maladaptive putamen gradient changes were more likely to relapse, suggesting a neural substrate for persistent, inflexible behaviors characteristic of the disorder.

Importantly, striatal gradient changes correlated with performance on the slip-of-action task (a measure of habitual versus goal-directed control), delay discounting (impulsivity and reward valuation), and circulating levels of ghrelin and desacyl ghrelin—hormones implicated in appetite regulation. This integration of neuroimaging, behavioral, and metabolic data provides a more comprehensive picture of the relapse process in AN than previously available.

One non-obvious implication is that the directionality and anatomical specificity of striatal reorganization—not just global volume changes—may serve as a more precise biomarker for identifying patients at highest risk of relapse, potentially enabling preemptive interventions.

Policy and Research Implications: Towards Targeted Neuromodulation

The identification of striatal reorganization as a relapse biomarker has significant implications for both clinical research and policy. Current treatments for AN, including cognitive-behavioral therapy and pharmacotherapy, have limited efficacy in preventing relapse. The new findings suggest that interventions targeting striatal circuits—such as neuromodulation, deep brain stimulation, or emerging psychedelic-assisted therapies—could be tailored to individuals with specific neural risk profiles.

• Biomarker development: Longitudinal MRI markers could be incorporated into clinical trials to stratify patients and monitor therapeutic response.
• Personalized medicine: Identifying patients with maladaptive striatal reorganization may inform the timing and type of intervention, potentially including novel neuromodulatory approaches.
• Regulatory guidance: Agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) may consider requiring or supporting biomarker-driven trial designs for future AN therapies.

While not directly studying psychedelics, the research provides a mechanistic foundation for testing whether psychedelic-assisted therapy—known to induce neuroplasticity and alter striatal connectivity—could remediate the neural patterns associated with relapse risk in AN and related disorders.

Risks, Unknowns, and Translational Challenges

Despite the promise of striatal biomarkers, several risks and unknowns remain. The predictive value of putamen gradient changes requires validation in larger, more diverse cohorts and across multiple time points. There is also a risk of overinterpreting correlational findings; while striatal changes are associated with relapse, causality has not been established.

Translating these biomarkers into clinical practice poses logistical and ethical challenges. MRI-based markers are costly and may not be accessible in all settings. Furthermore, interventions targeting striatal circuits—whether pharmacological, neuromodulatory, or psychedelic—carry their own risks, including potential for adverse neuropsychiatric effects and uncertain long-term outcomes.

Finally, the heterogeneity of AN and its comorbidities means that no single biomarker or intervention is likely to be universally effective. Ongoing research must address these complexities through rigorous, longitudinal, multi-site studies with transparent reporting of both positive and negative outcomes.

Looking Forward: Integrating Biomarkers into Next-Generation Treatment Trials

The discovery of striatal reorganization as a marker of relapse risk in AN marks a significant advance in understanding the neurobiology of recovery and recurrence. As the field moves toward precision psychiatry, integrating such biomarkers into clinical trial design could accelerate the development of targeted, mechanism-based interventions.

For psychedelic researchers and clinicians, the findings highlight a potential neural target—striatal plasticity—for future studies of psychedelic-assisted therapy in AN and other disorders characterized by maladaptive habitual behaviors. As regulatory agencies and funding bodies increasingly emphasize biomarker-driven approaches, early adoption of these markers could position research programs at the forefront of translational neuroscience and psychiatric innovation.

How we research: This article was written and reviewed by Dr. Alex Morgan, PhD (Neuroscience), on 2026-10-27. Primary source: OpenAlex study W7223696294.